Services Support
Online inquiry

For Research Use Only. Not For Clinical Use.

Contact us
  • Email:

Custom Episomal based Induced Pluripotent Stem Cell (iPSC) Reprogramming Service

Introduction Reprogramming by Episomal Vector Workflow What We Can Offer Customer Reviews FAQ

Introduction

Creative Biolabs' Custom Episomal based Induced Pluripotent Stem Cell (iPSC) Reprogramming Service uses EBV-derived oriP/EBNA-1 circular plasmids to generate high-quality, footprint-free iPSCs. These non-integrative plasmids replicate synchronously with the host genome without integration, balancing viral-like efficiency and non-integrative safety. Backed by published data, our turnkey solution delivers clinical-grade iPSCs with perfect genomic integrity, streamlining drug discovery, clinical trials, and toxicity testing.

Discover How We Can Help - Request a Consultation

Reprogramming by Episomal Vector

Core Information Analysis of Episomal Vectors

Episomal vectors are a type of non-integrative vector that can replicate autonomously, independent of the host genome in host cells. They can stably express target genes without integrating into the host chromosome and can be distributed to daughter cells through self-replication during cell division. Their core applications include gene delivery, cell reprogramming, and other scenarios.

Structural Composition (Typical Architecture)

  1. Origin of Replication (Ori): A core element that determines the autonomous replication ability of the vector. Common sources include oriP from Epstein-Barr Virus (EBV) and ori from Simian Virus 40 (SV40), which can utilize the host cell replication machinery to achieve vector amplification.
  2. Target Gene Expression Cassette: Contains a promoter (e.g., CMV, EF1α), target gene (e.g., reprogramming factors, therapeutic genes), and terminator (e.g., SV40 polyA), responsible for the transcription and expression regulation of the target gene.
  3. Selection Marker Gene: Used to screen cells that have successfully taken up the vector, commonly including antibiotic resistance genes (e.g., puromycin resistance gene) or fluorescent reporter genes (e.g., GFP).
  4. Maintenance Element: Such as the EBNA-1 gene from EBV, which can bind to oriP to ensure the stable distribution of the vector during cell division and reduce loss.
  5. Other Auxiliary Elements: Including multiple cloning sites (MCS, facilitating the insertion of target genes), replicons (adapting to prokaryotic cell amplification, e.g., pUC ori), etc.

Core Advantages

  1. No Genomic Integration Risk: Does not insert into the host chromosome, avoiding safety issues such as insertional mutagenesis and proto-oncogene activation caused by random integration, making it particularly suitable for clinical-grade cell modification.
  2. Stable and Controllable Expression: The vector replicates independently, so the expression level of the target gene is relatively stable; some vectors can regulate the expression timing through inducible promoters or be naturally lost with cell passage (when long-term expression is not required).
  3. Large Vector Capacity: Compared with viral vectors, episomal vectors can accommodate larger fragments of target genes (usually up to 10-20 kb), suitable for co-expression of multiple genes (e.g., simultaneous delivery of multiple reprogramming factors).
  4. Simple Operation and Low Cost: Can be delivered through non-viral methods such as electroporation and liposome transfection, without the need to construct viral particles. The preparation process is simple, and there are no biosafety risks associated with viruses.
  5. Broad Cell Compatibility: Has good transfection efficiency for various somatic cells (e.g., fibroblasts, PBMCs) and stem cells (e.g., iPSCs), with a wide range of applications.

Main Application Scenarios

  1. iPSC Reprogramming: One of the core applications. It can simultaneously deliver reprogramming factors such as Oct4, Sox2, Klf4, and c-Myc to achieve non-integrative reprogramming of somatic cells (e.g., PBMCs, fibroblasts), obtaining footprint-free iPSCs for cell therapy, disease modeling, etc.
  2. Gene Therapy: For the treatment of hereditary diseases (e.g., sickle cell anemia) or tumors, delivering therapeutic genes (e.g., function-restoring genes, CAR genes) to avoid integration risks and improve treatment safety.
  3. Gene Delivery in Basic Research: Used for short-term or long-term verification of gene functions, such as overexpressing or interfering with specific genes to study their roles in cell differentiation and signal pathway regulation.
  4. Cell Engineering Modification: Modifying immune cells (e.g., T cells, NK cells) or stem cells to endow them with specific functions (e.g., targeted killing, drug resistance) without affecting cell genomic stability.

Key Differences from Other Vectors (Core Advantages Highlighted)

Comparison Dimension Episomal Vectors Integrative Viral Vectors (e.g., Lentivirus) Non-integrative Viral Vectors (e.g., Sendai Virus)
Genomic Integration No Yes No
Vector Capacity Large (10-20 kb) Medium (8-10 kb) Small (usually < 8 kb)
Delivery Method Non-viral (Electroporation, Liposome) Viral Infection Viral Infection
Operation Complexity Low High (Virus Construction Required) Medium (Virus Preparation Required)
Clinical Safety High (No Integration Risk) Medium (Insertional Mutagenesis Risk) High
Applicable Scenarios iPSC Reprogramming, Gene Therapy, Basic Research Long-term Stable Expression, Basic Research Short-term Expression, iPSC Reprogramming

Workflow

What We Can Offer

At Creative Biolabs, we go beyond standard protocols to provide high-end, customized reprogramming solutions. We offer a robust toolkit designed to meet the specific requirements of complex pharmaceutical and academic research projects:

Fully Customized Reprogramming Strategies

Tailored vector selection and media formulations based on specific donor cell types (e.g., PBMCs, fibroblasts, or rare primary cells).

One-Stop Integration-Free Workflow

Complete management from initial cell isolation and expansion to large-scale iPSC banking.

Guaranteed Genomic Stability

Documentation and rigorous qPCR-based clearance procedures to ensure 100% "footprint-free" results approved by our Quality Assurance team.

Scalable Cell Banking

High-capacity cryopreservation and distribution services to maintain the stability of your cell lines for long-term clinical or HTS projects.

Optimized Factor Delivery

High-standard nucleofection protocols to maximize yield and efficiency while following strict Quality-by-Design (QbD) principles.

Comprehensive Regulatory Support

All procedures follow the basic principles of Good Manufacturing Practice (GMP) for downstream clinical translatability.

Advanced Characterization Tools

High-standard QC tools used to quantify and evaluate pluripotency markers, HLA typing, and trilineage potential.

Experience the Creative Biolabs Advantage - Get a Quote Today

Customer Reviews

FAQ

Q: Can this method be used on older donor samples or cells with reduced fitness?

A: Yes, our optimized nucleofection and culture protocols are specifically engineered to overcome the reduced proliferative capacity and lower reprogramming efficiency often associated with aged fibroblasts or PBMCs. By fine-tuning the metabolic environment and using specialized small-molecule cocktails, we can successfully revert senescent or "difficult-to-reprogram" cells back to a pluripotent state, ensuring that even challenging patient samples result in robust iPSC lines.

Q: How does this compare to Sendai Virus or mRNA-based reprogramming?

A: While all are non-integrative, episomal vectors are often preferred for clinical manufacturing and large-scale applications. Unlike Sendai Virus, episomal reprogramming avoids the introduction of live viral particles, which simplifies the regulatory and safety documentation for Phase I trials. Compared to mRNA, episomal delivery is significantly more cost-effective and less labor-intensive for high-throughput projects, offering a superior balance of efficiency, genomic safety, and ease of scalability.

Q: What is the success rate of reprogramming across different tissue types?

A: While reprogramming efficiency is inherently donor-dependent, our proprietary optimized platform maintains a near 100% project success rate. We typically generate and validate at least three high-quality clones for standard somatic cell types, such as fibroblasts and blood cells. This redundancy ensures that you have multiple clones to choose from for your downstream experiments, providing a safety net against clone-specific variability.

Q: Do you offer gene editing on these lines once they are generated?

A: Yes. Creative Biolabs provides a comprehensive suite of follow-up services. We can integrate CRISPR/Cas9 or other gene-editing technologies to create disease-corrected isogenic controls or reporter-labeled lines. This allows you to isolate the functional consequences of specific mutations within an expanded project, making our episomal reprogramming a perfect starting point for sophisticated disease modeling and drug screening.

Creative Biolabs offers the industry's most reliable Custom Episomal based Induced Pluripotent Stem Cell (iPSC) Reprogramming Service, ensuring your research starts with high-fidelity, footprint-free iPSCs. From initial sample processing to final pluripotency validation, our team provides the scientific rigor required to accelerate your therapeutic journey.

Contact Our Team for More Information and to Discuss Your Project

For Research Use Only. Not For Clinical Use.